Navigation Links
PharmaNova Fuels Business Growth with Lacerta Bio Partnership
Date:3/7/2011

VICTOR, N.Y., March 7, 2011 /PRNewswire/ -- PharmaNova, Inc. (PharmaNova) announces an agreement with Lacerta Bio, Inc. whereby Lacerta Bio's experienced team of business development professionals will supplement PharmaNova's team in the U.S. and U.K. to support its 2011 business growth and expansion initiatives. Emphasis will be on widening PharmaNova's partnering base for its innovative, nanoparticle technology, NovaSperse(SM), including existing NovaSperse(SM) new product opportunities and other projects that are available from PharmaNova for licensing and further development by third parties.

"We are delighted to be working with Lacerta Bio," said Rodney Brown, President of PharmaNova. "We have known both of the Lacerta Bio Managing Partners for several years, and are confident that working together, we can rapidly expand both our out-licensing and Fee-For-Service initiatives."

NovaSperse(SM), PharmaNova's proprietary, high drug load nanoparticle technology, utilizes minimal excipients and does not require complex equipment or processes. The NovaSperse(SM) process can be used to improve the solubility and enhance the delivery and pharmacokinetic properties of formulations in ophthalmics, dermatology, parenterals, and for other routes of administration.

"We have followed the progress made by PharmaNova over the past few years," said Dr. Anand R. Baichwal, Managing Partner of Lacerta Bio. "The NovaSperse(SM) technology is an excellent approach for rapidly developing new formulations with real therapeutic benefits, and we are excited to be a part of it."

About PharmaNova

PharmaNova is a privately held pharmaceutical company, which sub-licenses cutting-edge drug technology with its pioneering origins at the University of Rochester, and which develops and partners valuable new products to address underserved medical needs. Our products are created by re-positioning and enhancing the properties of known drugs using our proprietary NovaSperse(SM) nanoparticle drug delivery technology. A major additional component of our business is contractual formulation development work applying NovaSperse(SM) technology to support the repositioning and enhancement of client-owned products and compounds.

For more information, please visit http://www.pharmanovaco.com or contact Rodney A. Brown, President, PharmaNova, Inc. at +1-585-413-4721.

About Lacerta Bio

Lacerta Bio, Inc. is a business development and licensing consultancy for life sciences and other healthcare-related companies. Located in New York, Lacerta Bio assists life sciences companies and their investors identify, assess, and execute business development and licensing opportunities. The company also provides consulting on market opportunity assessments, competitive intelligence, pipeline analysis, interim business development management, and business plan and presentation development.

For more information, please visit http://www.lacertabio.com or contact Lacerta Bio, Inc. at +1 718 395 9371.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE PharmaNova, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
2. Paper or Plastic? Technology Fuels Gift Card Popularity and Access as an Alternative to Cash Incentives and Gifts
3. Kronos Announces First Quarter Business Update and Financial Results
4. Growth Achieved in Spherixs Health Sciences Consulting Business
5. ImaRx Therapeutics Transitions Business Strategy
6. Argonauta Communications Certified as Women-Owned Business by the Womens Business Enterprise National Council (WBENC)
7. New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
8. Small Business Innovation Research Program Awards Grant to Biomoda
9. American Dairy Provides Business Update
10. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
11. Pharmos Issues Business Update on Dextofisopam Trial and Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):